This study investigated the correlation of the presence of circulating tumor cells (CTCs) with clinical characteristics, and the predictive value of CTCs for progression-free survival (PFS) in patients with small-cell lung cancer (SCLC).
Methods
Samples were obtained from 42 patients with SCLC before and after the first cycle of chemotherapy. CTCs were quantitated by negative immunomagnetic enrichment and immunocytochemistry using anti-CD45 and anti-pancytokeratin antibodies.
Results
CTCs were positive (≥2) in 76.19% of patients with SCLC and negative in the control group. The presence of CTCs was positively correlated with 6 clinical characteristics. PFS was 6.055 and 10.670 months for patients with ≥2 and <2 CTCs/7.5 mL of blood before chemotherapy; after chemotherapy PFS was 4.862 and 10.535 months, respectively.
Conclusions
This study showed that both baseline CTC numbers and the change in CTC numbers after 1 cycle of chemotherapy are significant prognostic factors of PFS for SCLC.
Get full access to this article
View all access options for this article.
References
1.
SiegelRNaishadhamDJemalACancer statistics, 2012. CA Cancer J Clin. 2012;62 (1):10–29.
2.
GasparLEMcNamaraEJGayEGSmall-cell lung cancer: prognostic factors and changing treatment over 15 years. Clin Lung Cancer. 2012;13 (2):115–122.
3.
GovindanRPageNMorgenszternDChanging epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24 (28):4539–4544.
4.
AllardWJMateraJMillerMCTumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10 (20):6897–6904.
5.
CohenSJPuntCJIannottiNRelationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26 (19):3213–3221.
6.
CristofanilliMBuddGTEllisMJCirculating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351 (8):781–791.
7.
de BonoJSScherHIMontgomeryRBCirculating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14 (19):6302–6309.
8.
KrebsMGSloaneRPriestLEvaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol. 2011;29 (12):1556–1563.
9.
HodgkinsonCLMorrowCJLiYTumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med. 2014;20 (8):897–903.
10.
HiltermannTJPoreMMvan den BergACirculating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Ann Oncol. 2012;23 (11):2937–2942.
11.
HouJMKrebsMGLancashireLClinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol. 2012;30 (5):525–532.
12.
MillerMCDoyleGVTerstappenLWSignificance of circulating tumor cells detected by the CellSearch System in patients with metastatic breast colorectal and prostate cancer. J Oncol. 2010;2010:617421.
RiethdorfSFritscheHMüllerVDetection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res. 2007;13 (3):920–928.
15.
KraanJSleijferSStrijbosMHExternal quality assurance of circulating tumor cell enumeration using the CellSearch(®) system: a feasibility study. Cytometry B Clin Cytom. 2011;80 (2):112–118.
16.
StottSLHsuCHTsukrovDIIsolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci USA. 2010;107 (43):18392–18397.
17.
NaitoTTanakaFOnoAPrognostic impact of circulating tumor cells in patients with small cell lung cancer. J Thorac Oncol. 2012;7 (3):512–519.
18.
LalmahomedZSKraanJGratamaJWMostertBSleijferSVerhoefCCirculating tumor cells and sample size: the more, the better. J Clin Oncol. 2010;28 (17):e288–e289author reply e290.
19.
FriedlanderTWFongLThe end of the beginning: circulating tumor cells as a biomarker in castration-resistant prostate cancer. J Clin Oncol. 2014;32 (11):1104–1106.
20.
WeissensteinUSchumannAReifMLinkSToffol-SchmidtUDHeusserPDetection of circulating tumor cells in blood of metastatic breast cancer patients using a combination of cytokeratin and EpCAM antibodies. BMC Cancer. 2012;12 (1):206.
21.
Van der AuweraIPeetersDBenoyIHCirculating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer. Br J Cancer. 2010;102 (2):276–284.
22.
FaraceFMassardCVimondNA direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br J Cancer. 2011;105 (6):847–853.
23.
WichaMSHayesDFCirculating tumor cells: not all detected cells are bad and not all bad cells are detected. J Clin Oncol. 2011;29 (12):1508–1511.
24.
BuddGTCristofanilliMEllisMJCirculating tumor cells versus imaging predicting overall survival in metastatic breast cancer. Clin Cancer Res. 2006;12 (21):6403–6409.
25.
MatsusakaSChìnKOguraMCirculating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer. Cancer Sci. 2010;101 (4):1067–1071.
26.
De GiorgiUValeroVRohrenECirculating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Ann Oncol. 2010;21 (1):33–39.
27.
De GiorgiUValeroVRohrenECirculating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol. 2009;27 (20):3303–3311.
